AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
Potent small molecule xanthine oxidase inhibitors for the treatment of gout/hyperuricemia
Technology Application
- Compared to currently approved drugs, DHNB is a safe, effective, and stable XO inhibitor with similar potency as current therapies used to reduce uric acid production, but with much lower toxicity. Therefore, it is suitable for long term use to treat and/or prevent hyperuricemia and gout.- DHNB binds to the XO enzyme with high specificity. It may be used alone or in combination with traditional drugs to enhance efficacy and prevent drug resistance.- DHNB, but not other XO inhibitors, has beneficial antioxidant properties.- BCM researchers have developed novel small molecule XO inhibitors based on the chemical structure of DHNB.
Detailed Technology Description
None
Country/Region
USA
For more information, please click Here
